Wuhan Hvsen Biotechnology Co vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Wuhan Hvsen Biotechnology Co (300871) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Wuhan Hvsen Biotechnology Co leads: 8 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Wuhan Hvsen Biotechnology Co
9 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Wuhan Hvsen Biotechnology Co · Health Care
Vertex Pharmaceuticals · Health Care
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Wuhan Hvsen Biotechnology Co as the less overvalued of the two: Wuhan Hvsen Biotechnology Co trades at ¥22.95 versus a fair value of ¥19.35 (-16%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to Wuhan Hvsen Biotechnology Co
Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & CompanySee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.